Kết quả điều trị viêm gan virut B mạn bằng thuốc entercavir tại Bệnh viện Trung ương Thái Nguyên=Results of chronic hepatitis B virus treatment with entercavir at Thai Nguyen Central Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Oanh Đỗ, Thị Hương Lan Lê

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.27-34

Bộ sưu tập: Báo, Tạp chí

ID: 243728

Thêm vào giỏ

85 bệnh nhân viêm gan virut B mạn tuổi từ 20 đến 71 chưa từng điều trị hoặc ngưng điều trị với các thuốc kháng virus khác ít nhất 6 tháng trước khi bắt đầu được lựa chọn vào nghiên cứu. Bệnh nhân được làm xét nghiệm đo hoạt độ enzym gan, đo độ xơ hóa gan và đo tải lượng virus trước khi điều trị bằng entercavir 0,5 mg / ngày, thời gian điều trị 12 tháng. Đánh giá kết quả sinh hóa máu, mô học và tải lượng virus ở tháng thứ 3, 6, 12. Tác dụng phụ được theo dõi ghi nhận trong suốt quá trình điều trị. Kết quả sau 12 tháng điều trị 100% bệnh nhân có hoạt độ ALT trở về bình thường, mức độ xơ hóa gan trở về bình thường chiếm tỷ lệ rất cao 95,3%. Tải lượng HBVDNA trở về dưới ngường phát hiện là 85,8%. Tác dụng phụ không đáng kể, không có bệnh nhân nào phải ngưng thuốc điều trị. Kết luận: Entercavir có hiệu quả cao trong điều trị bệnh nhân viêm gan B mạn tính, an toàn, hầu như không có tác dụng phụ.85 patients with chronic hepatitis B virus aged 20 to 71 years old who had never been treated or stopped treatment with other antiviral drugs at least 6 months before the start of the study were selected. Patients were tested to measure liver enzyme activity, measure liver fibrosis, and measure viral load before treatment with entercavir 0.5 mg/day for a 12-month treatment period. Evaluate the results of blood chemistry, histology, and viral load at months 3, 6, and 12. Side effects are monitored and recorded throughout the treatment process. Results: After 12 months of treatment, 100% of patients had ALT activity returned to normal, and the level of liver fibrosis returned to normal, accounting for a very high rate of 95.3%. HBVDNA load returned below the detection limit of 85.8%. Side effects were insignificant
no patient had to stop treatment. Conclusion: Entercavir is highly effective in treating patients with chronic hepatitis B, is safe, and has almost no side effects.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR